v3.26.1
Note C - Investments in Unconsolidated Entities - Financial Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Revenue from Contract with Customer, Excluding Assessed Tax $ 1,024,000 $ 0  
Current assets 4,484,000 4,249,000  
Net loss (7,804,000) (2,055,000)  
Income (Loss) from Equity Method Investments (0) (434,000)  
Total assets 6,664,000 4,321,000  
Current liabilities 1,340,000 94,000  
Deficit 5,313,000 4,178,000 $ 645,000
Total liabilities and deficit 6,664,000 4,321,000  
CB Oncology Partners ("CBOP") [Member]      
Income (Loss) from Equity Method Investments (261,000) (278,000)  
CB Oncology Partners ("CBOP") [Member]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,414,000 1,475,000  
Current assets 348,000 347,000  
Net loss (870,000) (974,000)  
Noncurrent assets 1,185,000 1,785,000  
Total assets 1,533,000 2,132,000  
Current liabilities 4,648,000 4,067,000  
Noncurrent liabilities 3,263,000 3,572,000  
Deficit (6,378,000) (5,507,000)  
Total liabilities and deficit $ 1,533,000 $ 2,132,000